Tag: Jason Hardaway
PORTLAND, Ore. – May 9, 2016 — CiiTA founder and managing partner Jason Hardaway is invited to speak at the upcoming 340B Manufacturer Summit in Washington, DC August 18-19, 2016. This event, hosted by CBI, breaks down and clarifies the impending regulations impacting 340B programs, provides strategies to develop comprehensive self-disclosure response and auditing processes, and best…
Read MorePORTLAND, Ore. – April 25, 2016 — CiiTA founder and managing partner Jason Hardaway is invited to speak at the upcoming 15th Annual Medicaid and GP Congress in Orlando, Florida May 18-20, 2016. This event, hosted by CBI, is an invaluable opportunity to learn and receive updates on government pharmaceutical programs while also having the opportunity…
Read MoreAt present most manufacturers are not actively or effectively managing their exposure to 340B duplicate discounts. Current projections of the scope of the issue are severely limited by a lack of data, and many manufacturers are completely unaware of the significance of the problem. Additionally, the data required to identify duplicate claims is difficult to…
Read MorePORTLAND, Ore. – April 25, 2016 — CiiTA founder and managing partner Jason Hardaway is invited to speak at the upcoming third-annual National Leadership Summit on 340B in Washington, D.C. on May 17, 2016. This summit is the annual opportunity for stakeholders to engage in meaningful and transparent dialogue to ensure the 340B program’s future…
Read MoreThe P&T (Pharmacy and Therapeutics) Community online journal has published a response by CiiTA’s Managing Partner, Jason Hardaway, to their October 2015 report by Stephen Barlas about Congress’s 340B Program omnibus guidance issued by the Health Resources and Services Administration (HRSA). Mr. Hardaway’s article, titled 340B Program Puts Manufacturers At Risk of Duplicate Drug Discounts, addresses the material and financial risk of duplicate…
Read MoreIt should come as no surprise that CiiTA fully supports the 340B Program and recognizes the important financial role it plays in the healthcare safety net. What might be less obvious is that the vast majority of pharmaceutical manufacturers support 340B as well. (Full disclosure: CiiTA’s client base is almost exclusively drug companies.) The 340B…
Read MoreOver the past year, we here at CiiTA have become increasingly concerned about the potential 340B/Medicaid duplicate discount risk to manufacturers. We recently looked into this for a couple of our clients and found what amounts to a perfect storm of insidious financial exposure: 1) a surge in eligible claims thanks to the ACA-directed Medicaid…
Read MoreOn May 26, 2015 the Centers for Medicare & Medicaid Services (CMS) proposed to make Medicaid managed care organizations (MCOs) responsible for establishing procedures to prevent 340B duplicate discounts in the managed Medicaid setting. In the proposed rule, CMS has clarified that the onus will fall solely on the MCO to create models to prevent…
Read MoreJason Hardaway, CiiTA, LLC’s Managing Partner, has been invited as a panelist and discussion leader for a special session of the second annual National Leadership Summit on 340B. Held June 11, 2015 in Washington, DC, the invitation-only event will provide the opportunity for stakeholders to come together to engage in meaningful and transparent dialogue to ensure the…
Read MoreDevelop Your 340B Strategy
CiiTA has, through extensive experience, developed a set of best practices to help guide you through the creation of your 340B strategy. Download our process document to facilitate the development of your strategy.